Skip to main content

Advertisement

Table 1 Study characteristics

From: Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: A systematic review and meta-analysis

  Psychotherapy Medication Diagnosis Mean age of sample % female in sample N se Treatment duration (weeks) N rand Country
Browne 2002[26] IPT Sertraline (SSRI) Dys, DD 42.2 68 12 24 476 Canada
deMello 2001[27] IPT Moclobemide Dys, DD 38.8 80 16 32 35 Brazil
Keller 2000[28] CBASP Nefazodone cMD, rec, DD 43.0 65 16 12 453 USA
Kocsis 2009[13] CBASP/BSP SSRIs cMD, rec, DD 45.4 55 16/18 12 491 USA
Markowitz 2005[29] IPT Sertraline (SSRI) Dys 42.3 63 16 16 45 USA
Miller 1999[30] CBT Amitriptyline/Desipramine Dys 37.4 81 40 20 26 USA
Ravindran 1999[31] CBT Sertraline (SSRI) Dys 38.0 58 12 12 47 Canada
Schramm 2008[32] IPT Sertraline (SSRI)/Amitriptyline cMD, DD 42.8 67 15 5 45 Germany
  1. N se = number of psychotherapy sessions; N rand = patients randomized to relevant study arms; IPT = Interpersonal Psychotherapy; CBASP = Cognitive Behavioural Analysis System of Psychotherapy; BSP = Brief Supportive Psychotherapy; CBT = Cognitive Behavioural Therapy; Dys = dysthymia; DD = double depression; cMD = chronic major depression; rec = recurrent depression without complete remission between episodes.